|
FDA approves GlaxoSmithKline's Arnuity Ellipta for treatment of asthma
News-Medical.net GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 … |
View full post on asthma – Google News